Aurobindo Pharma has entered into a non-exclusive voluntary licensing agreement with MSD (trade name of Merck & Co., Inc., Rahway, N.J., USA. Aurobindo Pharma is among a select group of global generic manufacturers to have signed this agreement. The royalty-free agreement will enable supply of generic alimatravir to cover 129 Low- & Middle-Income Countries (LMICs) which account for the majority of new HIV diagnoses globally, subject to applicable regulatory approvals and requirements.
Executing these agreements before Phase 3 trial enrollment is completed is a first in HIV prevention and is intended to enable the right scale-up where Aurobindo Pharma is licensed to manufacture and supply generic alimatravir, which will meet internationally recognized standards following regulatory approvals.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
